Risk of late health effects after soft-tissue sarcomas in childhood – a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia research programme

References

• Bisogno GA. Solid tumors of childhood – soft tissue sarcoma. In: Estlin EJ GR, Wynn RF, ed. Pediatric hematology and oncology: scientific principles and clinical practice. 1st ed. Oxford, UK: Blackwell Publishing Ltd; 2010. p. 216–233.
   Google Scholar
• M. Fatih Okcu ASP, John Hicks, Lynn Millon, Richard J. Andrassy, and Sheri L. Spunt. The NonRhabdymyosarcoma soft tissue sarcomas. In: Poplack PAPaDG, ed. Principles and practice of pediatric oncology. Philadelphia: Wolters Kluwer; 2011. p. 954–988.
   Google Scholar
• Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5–a population-based study. Lancet Oncol. 2014;15(1):35–47.
   PubMed Web of Science ®Google Scholar
• Green DM, Kun LE, Matthay KK, et al. Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatr Blood Cancer. 2013;60(7):1083–1094.
   PubMed Web of Science ®Google Scholar
• Punyko JA, Mertens AC, Baker KS, et al. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer. 2005;103(7):1475–1483.
   PubMed Web of Science ®Google Scholar
• Affinita MC, Ferrari A, Milano GM, et al. Long-term results in children with head and neck rhabdomyosarcoma: a report from the Italian Soft Tissue Sarcoma Committee. Pediatr Blood Cancer. 2018;65(3):e26876.
   Web of Science ®Google Scholar
• Bisogno G, Jenney M, Bergeron C, et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 2018;19(8):1061–1071.
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Sanchez de Toledo J, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol. 2012;30(20):2457–2465.
   PubMed Web of Science ®Google Scholar
• Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005;23(12):2618–2628.
   PubMed Web of Science ®Google Scholar
• Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009;27(9):1446–1455.
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 1999;17(12):3706–3719.
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Jurgens H, Winkler K, et al. Treatment of soft tissue sarcoma in childhood and adolescence. a report of the German Cooperative Soft Tissue Sarcoma Study. Cancer. 1992;70(10):2557–2567.
   PubMed Web of Science ®Google Scholar
• Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol. 2009;27(31):5182–5188.
   PubMed Web of Science ®Google Scholar
• Crist W, Gehan EA, Ragab AH, et al. The third intergroup rhabdomyosarcoma study. J Clin Oncol. 1995;13(3):610–630.
   PubMed Web of Science ®Google Scholar
• Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19(12):3091–3102.
   PubMed Web of Science ®Google Scholar
• Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer. 2014;14(1):61–70.
   PubMed Web of Science ®Google Scholar
• Norris RE, Adamson PC. Challenges and opportunities in childhood cancer drug development. Nat Rev Cancer. 2012;12(11):776–782.
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Robison LL. Childhood cancer survivors, late effects, and a new model for understanding survivorship. JAMA. 2007;297(24):2762–2764.
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–1582.
   PubMed Web of Science ®Google Scholar
• de Fine Licht S, Winther JF, Gudmundsdottir T, et al. Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a population-based cohort study. Lancet. 2014;383(9933):1981–1989.
   PubMed Web of Science ®Google Scholar
• Punyko JA, Mertens AC, Gurney JG, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2005;44(7):643–653.
   PubMed Web of Science ®Google Scholar
• Norsker FN, Rechnitzer C, Cederkvist L, et al. Somatic late effects in 5-year survivors of neuroblastoma: a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia study. Int J Cancer. 2018;143(12):3083–3096.
   PubMed Web of Science ®Google Scholar
• Gonzalez CD, Randall RL, Wright J, et al. Long-term survivors of childhood bone and soft tissue sarcomas are at risk of hospitalization. Pediatr Blood Cancer. 2017;64(6):e26371.
   Web of Science ®Google Scholar
• Gibson TM, Mostoufi-Moab S, Stratton KL, et al. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2018;19(12):1590–1601.
   PubMed Web of Science ®Google Scholar
• Fromm M, Littman P, Raney RB, et al. Late effects after treatment of twenty children with soft tissue sarcomas of the head and neck. Experience at a single institution with a review of the literature. Cancer. 1986;57(10):2070–2076.
   PubMed Web of Science ®Google Scholar
• Nag S, Tippin D, Ruymann FB. Long-term morbidity in children treated with fractionated high-dose-rate brachytherapy for soft tissue sarcomas. J Pediatr Hematol Oncol. 2003;25(6):448–452.
   PubMed Web of Science ®Google Scholar
• Asdahl PH, Winther JF, Bonnesen TG, et al. The Adult Life After Childhood Cancer in Scandinavia (ALiCCS) study: design and characteristics. Pediatr Blood Cancer. 2015;62(12):2204–2210.
   PubMed Web of Science ®Google Scholar
• Boshuizen H, Feskens E. Fitting additive Poisson models. Epidemiol Perspect Innov. 2010;7:4.
   PubMedGoogle Scholar
• Dong H, Robison LL, Leisenring WM, Martin LJ, et al. Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count. Am J Epidemiol. 2015;181(7):532–540.
   PubMed Web of Science ®Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16(3):1141–1154.
   Web of Science ®Google Scholar
• Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. Biometrics. 2000;56(2):554–562.
   PubMed Web of Science ®Google Scholar
• Boschini C, Andersen KK, Scheike TH. Excess risk estimation for matched cohort survival data. Stat Methods Med Res. 2019;28(10–11):3451–3465.
   PubMed Web of Science ®Google Scholar
• Buuren S, Groothuis-Oudshoorn K. MICE: multivariate imputation by chained equations in R. J Stat Soft. 2011;45(3):1–67.
   Web of Science ®Google Scholar
• Kurt BA, Nolan VG, Ness KK, et al. Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. Pediatr Blood Cancer. 2012;59(1):126–132.
   PubMed Web of Science ®Google Scholar
• Nandagopal R, Laverdiere C, Mulrooney D, et al. Endocrine late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Horm Res. 2008;69(2):65–74.
   PubMedGoogle Scholar
• Ingimarsdottir IJ, Rusch E, Engholm G, et al. Quality assessment of prostate cancer reports to the Danish Cancer Registry. Acta Oncol. 2016;55(1):24–29.
   PubMed Web of Science ®Google Scholar
• Korhonen P, Malila N, Pukkala E, et al. The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol. 2002;41(4):381–388.
   PubMed Web of Science ®Google Scholar